Neda Rasouli

17PUBLICATIONS
52CO-AUTHORS
HaematologyMolecular targetsExercise physiologyEpidemiological modellingGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 21, 2026
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?

|Dec 23, 2025
Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).

Steven E Kahn, Mark Tripputi, John M Lachin

|Jun 21, 2025
Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.

Neda Rasouli, Ecenur Guder Arslan, Andrei-Mircea Catarig

|Feb 25, 2025
Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).

Kristina M Utzschneider, Mark Tripputi, Nicole M Butera

|Nov 12, 2024
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics.

Christophe De Block, Jennifer Peleshok, John P H Wilding

|Oct 18, 2024
Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.

Marc P Bonaca, Andrei-Mircea Catarig, Yasemin Hansen

Pageof 3

Frequent Collaborators

6 joint publications

Kristina Utzschneider

5 joint publications

Ralph A DeFronzo

4 joint publications

Ashok Balasubramanyam

4 joint publications

William I Sivitz